Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Thomas McCoy Roberts, Ph.D.

Concepts

This page shows the publications Thomas Roberts has written about Enzyme Inhibitors.
Connection Strength

0.223
  1. A strategy for screening anti-tumor drugs utilizing oncogenes encoded in retroviral vectors. Int J Cancer. 1996 Jun 11; 66(6):753-9.
    View in: PubMed
    Score: 0.070
  2. PI3 kinases in cancer: from oncogene artifact to leading cancer target. Sci STKE. 2006 Dec 12; 2006(365):pe52.
    View in: PubMed
    Score: 0.036
  3. A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cells. Cancer Cell. 2003 Dec; 4(6):463-76.
    View in: PubMed
    Score: 0.030
  4. Dissection of angiogenic signaling in zebrafish using a chemical genetic approach. Cancer Cell. 2002 Apr; 1(3):257-67.
    View in: PubMed
    Score: 0.026
  5. Tyrosine phosphorylation of the proto-oncoprotein Raf-1 is regulated by Raf-1 itself and the phosphatase Cdc25A. Mol Cell Biol. 1999 Jul; 19(7):4819-24.
    View in: PubMed
    Score: 0.022
  6. PI3 kinase alpha and delta promote hematopoietic stem cell activation. JCI Insight. 2019 05 23; 5.
    View in: PubMed
    Score: 0.022
  7. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009 Aug; 8(8):627-44.
    View in: PubMed
    Score: 0.011
  8. Platelet-derived growth factor stimulation of monocyte chemoattractant protein-1 gene expression is mediated by transient activation of the phosphoinositide 3-kinase signal transduction pathway. J Biol Chem. 1999 Oct 22; 274(43):31062-7.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.